 CAMBRIDGE, Mass., Jan. 05, 2022 GLOBE NEWSWIRE -- Genocea Biosciences, Inc. Nasdaq: GNCA, a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. 